(26 May 2025 – Hong Kong) Gleneagles Hospital Hong Kong (Gleneagles) and Emerging Viral Diagnostics (HK) Limited (EVDL) today announced a collaboration to integrate cutting-edge medical technologies into clinical practice, enhancing the quality and efficiency of diagnostic services in Hong Kong. Under this partnership, Gleneagles will adopt EVDL’s innovative diagnostics system for its laboratory and telemedicine services. 

EVDL, a Hong Kong-based MedTech company, has developed the Avalon Automated Multiplex System (AAMST), a groundbreaking nucleic acid testing platform capable of detecting and identifying 45 respiratory pathogen targets—including viruses, bacteria, and fungi—in just 1.5 hours. This makes it the most comprehensive molecular diagnostic platform available globally. 

The technology originated from fundamental research at local universities in 2016 and was scaled for industrial use during the COVID-19 pandemic, with full local production established in Hong Kong. Recognized for its potential impact, AAMST was featured in the World Health Organization’s (WHO) 2024 Compendium of Innovative Health Technologies for Low-Resource Settings and was among the first projects awarded under the HKSAR Government’s “Research, Academic and Industry Sectors One-plus Scheme” (RAISe+). This collaboration with Hong Kong Baptist University exemplifies successful industry-academia-research synergy, driving high-quality innovation in Hong Kong. 

Gleneagles will introduce this innovative technology into its laboratory testing services, with an aim to provide faster, more accurate and comprehensive diagnostic services. The hospital also plans to integrate its telemedicine and remote care services with the testing services supported by EVDL’s technology, building a seamless remote patient care journey. The service chain will be supported by efficient logistic arrangements for the testing samples to ensure timely diagnosis and treatment for patients with suspected respiratory tract infections. In addition to enhancing public health response capabilities, the diagnostics technologies will empower clinicians to determine the need of prescribing antibiotics, aligning with the hospital’s vision of antibiotic stewardship. 

The agreement was signed by Dr Kenneth Tsang, Regional CEO of IHH Healthcare North Asia and CEO of Gleneagles Hospital Hong Kong, and Professor Terence Lau, Co-Founder and President of EVDL. The ceremony was witnessed by distinguished guests, including Dr Prem Kumar Nair (Group CEO, IHH Healthcare), Professor Alexander Wai (President, Hong Kong Baptist University), Professor Manson Fok (Co-Founder and Chairman of EVDL and Dean of Faculty of Medicine and President of University Hospital, Macau University of Science and Technology), Mr Paul Lau (Chief Financial Officer, Gleneagles Hospital Hong Kong) and Dr Patrick Lau (Deputy Executive Director, HKTDC). 

Dr Kenneth Tsang remarked, “Embracing continuous improvement in our delivery of excellent patient care and outcomes, Gleneagles has been actively partnering with different universities, startups and medical technology companies to drive advancement of healthcare innovation and facilitate translation of cutting-edge medical technologies to clinical solutions. Our collaboration with homegrown EVDL to introduce this locally-developed diagnostics technology will further strengthen our testing and remote care capabilities, allowing us to provide faster, more accurate diagnostics services and ultimately benefiting more patients.” 

Professor Terence Lau added: “Bridging the gap between medical innovation and clinical application is critical. This partnership with Gleneagles allows us to deploy AAMST for real-world impact, improving diagnostics and promoting responsible antibiotic use. We are grateful for the HKSAR Government’s support through initiatives like RAISe+, which accelerates transformative healthcare solutions.” 

The signing ceremony was held at the Asia Summit on Global Health 2025, co-organised by the Government of the HKSAR and the Hong Kong Trade Development Council. This collaboration was facilitated through connections made at the last edition of the Summit. 

Gleneagles and EVDL will continue to explore new areas of collaboration. This partnership exemplifies their shared commitment to multidisciplinary innovation and translation of research achievements. The joint effort is poised to facilitate the commercialisation and clinical application of cutting-edge biotechnologies to address local needs and deliver impactful healthcare innovations. Gleneagles and EVDL anticipate this collaboration will serve as a significant step in supporting the Hong Kong Government's alignment with Mainland China's healthcare reforms, while making positive contributions to healthcare technology advancement. 

(Front row) Dr Kenneth Tsang, Regional Chief Executive Officer of IHH Healthcare North Asia and Chief Executive Officer of Gleneagles Hospital Hong Kong (left); and Professor Terence Lau, Co-Founder & President of Emerging Viral Diagnostics (HK) Limited (right) sign a collaboration agreement to foster the applications of medical innovative technologies, witnessed by (back row from left) Mr Paul Lau, Chief Financial Officer of Gleneagles Hospital Hong Kong; Professor Alexander Ping-kong Wai, President and Vice-Chancellor of Hong Kong Baptist University; Dr Prem Kumar Nair, Group Chief Executive Officer of IHH Healthcare; and Professor Manson Fok, Co-Founder & Chairman of Emerging Viral Diagnostics (HK) Limited, and Dean of Faculty of Medicine and President of University Hospital, Macau University of Science and Technology; and Dr Patrick Lau, Deputy Executive Director of the Hong Kong Trade Development Council.  

– END – 
 

Gleneagles Hospital Hong Kong 

Located in Hong Kong Island South, Gleneagles Hospital Hong Kong (Gleneagles) is a multi-specialty private hospital with cutting-edge medical equipment and a comprehensive range of clinical services spanning more than 35 specialties and subspecialties. As Hong Kong’s top-notch private teaching hospital, Gleneagles also contributes to the training and development of healthcare professionals and advancement of clinical research. Gleneagles is jointly developed by IHH Healthcare and CTF Services Limited, with The University of Hong Kong as its exclusive clinical partner. 

Gleneagles Hospital Hong Kong is part of IHH Healthcare, one of the world’s largest healthcare providers. With its full spectrum of integrated services, dedicated people, reach and scale, and commitment to quality and safety, IHH aspires to be the world’s most trusted healthcare services network, united by a single purpose: to touch lives and transform care. 

More information on Gleneagles Hospital Hong Kong can be found at https://gleneagles.hk. 

Emerging Viral Diagnostics (HK) Limited 

Emerging Viral Diagnostics (EVDL) is a Hong Kong-based MedTech company that integrates academic, industrial, and research expertise to transform unmet medical needs into practical innovative solutions. Their " Avalon Automated Multiplex System " has been recommended in the 2024 Compendium of Innovative Health Technologies for Low-resource Settings published by the World Health Organization and has received international recognition. EVDL aspires to become a worldwide leader in diagnostic industry and to push Diagnosis beyond Boundaries. 

More information on Emerging Viral Diagnostics (HK) Limited can found at https://emvdl.com. 

Media Enquiries

Tracy Chow 
Gleneagles Hospital Hong Kong 
Tel: +852 3153 9330 
Email: tracy.chow@gleneagles.hk 

Bianca Ko 
Emerging Viral Diagnostics (HK) Limited 
Tel: +852 2389 6899 
Email: kotyb@emvdl.com